Novel Class of Inhibitors for Fibrosing Disorders and Cancer

Tech ID: pta000824




Chronic pancreatitis (CP) is a persistent inflammation of the pancreas that leads to damage of parenchyma, gradual fibrotic replacement of the gland, and serious complications, including loss of exocrine and endocrine function and cancer. No effective anti-inflammatory and anti-fibrotic therapies exist to date because of the limited understanding of the key driving signaling mechanisms in pancreatic stellate cells. The inventors have identified a novel targetable pathway that is involved in chronic pancreatitis, fibrosis, and also likely in inflammation and fibrosis of  the liver, lung, intestine, and other organs.


Technology Description


• The inventors have identified a novel targetable pathway in human chronic pancreatitis and fibrosis, and perhaps in inflammation and fibrosis of liver, lung, intestine, and other organs. This is based on in vitro data that inhibitors against the target can reduce target mediated chemotaxis signaling in the stellate cells isolated from chronic pancreatitis patients.

• Activated stellate cells and myofibroblasts are involved in carcinogenesis of pancreas and other disorders. This new class of inhibitor will have benefit in cancers where myofibroblasts are involved.


Stage of Development


In vivo data.




New use of existing drug -- Our team would be interested in collaboration with a capable industry partner to further test the inhibitors in preclinical Investigational New Drug (IND) enabling studies to advance the drug candidates toward human clinical trials. 




The invention provides the foundation for designing a new class of drugs and potentially new uses of existing drugs to treat fibrosing disorders and cancer.


Intellectual Property


PCT application PCT/US2015/048202 nationalized in US, Europe, and Japan.


Patent Information:
For Information, Contact:
Wenyue Du
Senior Associate - IP Management & Licensing
Andrzej Ptasznik
Stephen Pandol
Hung Pham